84 related articles for article (PubMed ID: 18069632)
1. [Correlation of tenascin-C degradation fragment with recurrence and/or metastasis in early non-small-cell lung cancer].
Cai M; Xie ZT; Weng Y; Chang Q; Chang JH
Zhonghua Zhong Liu Za Zhi; 2007 Jul; 29(7):518-21. PubMed ID: 18069632
[TBL] [Abstract][Full Text] [Related]
2. Degradation of tenascin-C and activity of matrix metalloproteinase-2 are associated with tumor recurrence in early stage non-small cell lung cancer.
Cai M; Onoda K; Takao M; Kyoko IY; Shimpo H; Yoshida T; Yada I
Clin Cancer Res; 2002 Apr; 8(4):1152-6. PubMed ID: 11948127
[TBL] [Abstract][Full Text] [Related]
3. Elevated activities of MMP-2 in the non-tumorous lung tissues of curatively resected stage I NSCLC patients are associated with tumor recurrence and a poor survival.
Kim SH; Choi HY; Lee J; Son DS; Lee HS; Song IS; Lim YS; Hong YS; Kim J; Choi YS
J Surg Oncol; 2007 Mar; 95(4):337-46. PubMed ID: 17326127
[TBL] [Abstract][Full Text] [Related]
4. Tissue inhibitor of metalloproteinase 1 is an independent predictor of prognosis in patients with nonsmall cell lung carcinoma who undergo resection with curative intent.
Gouyer V; Conti M; Devos P; Zerimech F; Copin MC; Créme E; Wurtz A; Porte H; Huet G
Cancer; 2005 Apr; 103(8):1676-84. PubMed ID: 15754326
[TBL] [Abstract][Full Text] [Related]
5. Tenascin-C, over expressed in lung cancer down regulates effector functions of tumor infiltrating lymphocytes.
Parekh K; Ramachandran S; Cooper J; Bigner D; Patterson A; Mohanakumar T
Lung Cancer; 2005 Jan; 47(1):17-29. PubMed ID: 15603851
[TBL] [Abstract][Full Text] [Related]
6. Serum tenascin-C as a potential predictive marker of angiogenesis in non-small cell lung cancer.
Ishiwata T; Takahashi K; Shimanuki Y; Ohashi R; Cui R; Takahashi F; Shimizu K; Miura K; Fukuchi Y
Anticancer Res; 2005; 25(1B):489-95. PubMed ID: 15816617
[TBL] [Abstract][Full Text] [Related]
7. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
[TBL] [Abstract][Full Text] [Related]
8. [Prognostic value of expression of FASE, HER-2/neu, bcl-2 and p53 in stage I non-small cell lung cancer].
Wang Y; Zhang XR; Fu J; Tan W; Zhang W
Zhonghua Zhong Liu Za Zhi; 2004 Jun; 26(6):369-72. PubMed ID: 15312350
[TBL] [Abstract][Full Text] [Related]
9. Matrix metalloproteinase-12 expression correlates with local recurrence and metastatic disease in non-small cell lung cancer patients.
Hofmann HS; Hansen G; Richter G; Taege C; Simm A; Silber RE; Burdach S
Clin Cancer Res; 2005 Feb; 11(3):1086-92. PubMed ID: 15709175
[TBL] [Abstract][Full Text] [Related]
10. Biological and clinical significance of MMP-2, MMP-9, TIMP-1 and TIMP-2 in non-small cell lung cancer.
Iniesta P; Morán A; De Juan C; Gómez A; Hernando F; García-Aranda C; Frías C; Díaz-López A; Rodríguez-Jiménez FJ; Balibrea JL; Benito M
Oncol Rep; 2007 Jan; 17(1):217-23. PubMed ID: 17143501
[TBL] [Abstract][Full Text] [Related]
11. [Expressions of vascular endothelial growth factor C and matrix metalloproteinases-2 and prognosis of non-small cell lung carcinoma].
Zhang HZ; Wei YP; Li HG; Wang M; Liu JG; Wu C
Nan Fang Yi Ke Da Xue Xue Bao; 2006 Sep; 26(9):1307-10. PubMed ID: 16982442
[TBL] [Abstract][Full Text] [Related]
12. [The serum concentration of metalloproteinase 9 and 2 in non-small cell lung cancer patients].
Kopczyńska E; Dancewicz M; Kowalewski J; Kardymowicz H; Tyrakowski T
Pol Merkur Lekarski; 2007 Jun; 22(132):539-41. PubMed ID: 17874625
[TBL] [Abstract][Full Text] [Related]
13. [Comparison of the characteristics in recurrence and metastasis between bronchioloalveolar carcinoma and other lung adenocarcinomas].
Zhong XJ; Li DT; Li XL; Mu DB; Zhang XG; Luo JY
Ai Zheng; 2007 Jul; 26(7):785-9. PubMed ID: 17626761
[TBL] [Abstract][Full Text] [Related]
14. Completely resected N1 non-small cell lung cancer: factors affecting recurrence and long-term survival.
Fujimoto T; Cassivi SD; Yang P; Barnes SA; Nichols FC; Deschamps C; Allen MS; Pairolero PC
J Thorac Cardiovasc Surg; 2006 Sep; 132(3):499-506. PubMed ID: 16935101
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of matrix metalloproteinase 2 predicts unfavorable outcome in early-stage non-small cell lung cancer.
Passlick B; Sienel W; Seen-Hibler R; Wöckel W; Thetter O; Mutschler W; Pantel K
Clin Cancer Res; 2000 Oct; 6(10):3944-8. PubMed ID: 11051242
[TBL] [Abstract][Full Text] [Related]
16. [Predicting efficacy of neoadjuvant cheomotherapy on resectable stage IIIA non-small cell lung cancer by multi-gene expressions].
Cheng C; Wu YL; Gu LJ; Chen G; Weng YM; Feng WN; Zhong WZ
Ai Zheng; 2005 Jul; 24(7):846-9. PubMed ID: 16004813
[TBL] [Abstract][Full Text] [Related]
17. No association between the C-1562T polymorphism in the promoter of matrix metalloproteinase-9 gene and non-small cell lung carcinoma.
Wang Y; Fang S; Wei L; Wang R; Jin X; Wen D; Li Y; Guo W; Wang N; Zhang J
Lung Cancer; 2005 Aug; 49(2):155-61. PubMed ID: 15949868
[TBL] [Abstract][Full Text] [Related]
18. Serum protein expression predicts recurrence in patients with early-stage lung cancer after resection.
D'Amico TA; Brooks KR; Joshi MB; Conlon D; Herndon J; Petersen RP; Harpole DH
Ann Thorac Surg; 2006 Jun; 81(6):1982-7; discussion 1987. PubMed ID: 16731117
[TBL] [Abstract][Full Text] [Related]
19. Serum Sialyl Lewis x and cytokeratin 19 fragment as predictive factors for recurrence in patients with stage I non-small cell lung cancer.
Mizuguchi S; Nishiyama N; Iwata T; Nishida T; Izumi N; Tsukioka T; Inoue K; Uenishi T; Wakasa K; Suehiro S
Lung Cancer; 2007 Dec; 58(3):369-75. PubMed ID: 17697728
[TBL] [Abstract][Full Text] [Related]
20. [Expression and clinical significance of vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 in non-small cell lung carcinoma].
Lu ZQ; Li HG; Xie DR; Zhang HZ; Shen XM; Zeng YJ; Zeng H
Ai Zheng; 2005 Sep; 24(9):1132-5. PubMed ID: 16159440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
